American Shared Hospital Services (AMS) Q2 2026 earnings review
Top-Line Acceleration Masked by Balance Sheet Life Support
AMS delivered a strong 19% YoY revenue increase to $8.4 million in Q2, breaking a multi-quarter streak of stagnation. The transition to a Direct Patient Services model is working on the top line, with that segment accelerating 40% YoY. However, the volume recovery did not reach the bottom line. Net loss nearly doubled to $514,000 as the company absorbed a massive $909,000 credit loss allowance for aging receivables and $285,000 in legal fees to restructure its debt. With gross margins continuing to compress and the company relying on a $2.0 million insider loan from its Executive Chairman to maintain liquidity, the financial foundation remains highly precarious.
🐂 Bull Case
The strategic pivot away from legacy equipment leasing is bearing fruit. Direct Patient Services grew 40% YoY to $4.9M, proving the company can successfully drive patient volumes at its Rhode Island and Mexico facilities.
Despite net losses, the company generated $4.4M in operating cash flow in H1 2026, restoring its cash balance to $6.8M and successfully navigating a critical debt covenant crisis from late 2025.
🐻 Bear Case
Gross margin declined to 17.0% from 23.0% a year ago. Trading high-margin leasing revenue for lower-margin direct patient care structurally caps near-term profitability.
A $909K write-off for older receivables points to poor revenue cycle management. Needing a $2M subordinated loan from the Executive Chairman indicates traditional financing avenues remain restricted.
⚖️ Verdict: 🔴
Bearish. While 19% revenue growth is an undeniable operational win, the quality of earnings is deeply concerning. Rampant bad debt write-offs, contracting margins, and reliance on insider bridge loans severely outweigh the top-line recovery.
Key Themes
Direct Patient Services Driving Top-Line Acceleration
The Direct Patient Services segment is the undisputed growth engine, accelerating 40% YoY to $4.9 million in Q2. This was driven by higher procedure volumes at the Rhode Island radiation therapy centers and the newer Puebla, Mexico facility. This segment now firmly dictates the company's trajectory, offsetting the stable but stagnant legacy leasing business.
PBRT Benefiting from Macro Reimbursement Tailwinds
Proton Beam Radiation Therapy (PBRT) revenue rebounded, rising 22% YoY to $2.3 million. Management explicitly cited higher average reimbursement per treatment alongside a 10% volume increase. In a challenging healthcare macro environment where labor and equipment costs are rising, favorable reimbursement adjustments act as a critical operational lever.
Esprit Upgrade Catalyzing International Growth
International Gamma Knife operations are showing a stable, sustained recovery, with H1 2026 revenue up 56% to $2.7 million. This is directly attributable to technological innovation: the installation of the Esprit system upgrade in Lima, Peru, which significantly reduced treatment times and expanded patient throughput.
Red Flag: Collections Contradict 'Strong' Execution Narrative
Management claimed their operating business is 'performing well,' but the financials revealed a $909,000 allowance for credit losses for accounts receivable dated prior to May 31, 2025. Writing off nearly $1 million in aging AR suggests severe breakdowns in revenue cycle management, likely tied to the integration of the Rhode Island acquisitions, calling into question the quality of reported revenue.
Structural Gross Margin Compression
The business model shift is decelerating profitability. Q2 Gross Margin fell to $1.4 million (17.0% of revenue) compared to $1.6 million (23.0% of revenue) a year ago. Direct Patient Services requires heavier staffing and facility overhead than equipment leasing, resulting in negative operating leverage despite strong sales growth.
Balance Sheet Sustained by Insider Life Support
The company entered a Third Amendment and Forbearance Agreement with Fifth Third Bank, costing $285,000 in legal fees during Q2. More alarming, AMS had to secure $2.0 million in subordinated financing from an entity controlled by its Executive Chairman. Relying on insider bridge loans to fund working capital highlights acute distress in their capital structure.
Other KPIs
Reversing the cash burn trend seen in late 2025. Despite posting a $1.1M net loss in H1, disciplined working capital management—and potentially delayed vendor payments—allowed the company to generate substantial operating cash, pushing the total cash balance from $3.7M at year-end to $6.8M.
Decelerating 21% from $1.70 million in the prior-year quarter. When adjusted for the bad debt write-offs and legal fees, underlying cash earnings are still shrinking despite top-line growth, heavily underscoring the margin challenges of the new direct care business model.
Key Questions
Origins of the $909K Bad Debt
The $909,000 credit loss allowance for aging receivables wipes out a significant portion of quarterly gross profit. Were these billing issues isolated to the Rhode Island acquisition integration, and are there further legacy AR risks remaining on the balance sheet?
Runway Provided by Insider Loan
With the Third Amendment secured and a $2.0 million subordinated loan injected by the Executive Chairman, exactly how many quarters of liquidity runway does this buy the company before a permanent capital restructuring is necessary?
Long-Term Margin Targets
Given the structural compression in gross margins caused by the shift to Direct Patient Services, what is management's target margin profile once the newer facilities in Rhode Island and Mexico reach full utilization?